Progress of cellular immunotherapy in multiple myeloma
10.3760/cma.j.issn.1009-9921.2018.12.016
- VernacularTitle:多发性骨髓瘤细胞免疫治疗研究进展
- Author:
Tianheng HE
1
;
Wenming CHEN
Author Information
1. 100020,首都医科大学附属北京朝阳医院血液科
- Keywords:
Multiple myeloma;
Immunity,cellular;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2018;27(12):765-768
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a kind of refractory diseases, characterized by clonal proliferation of malignant plasma cells. Thanks to the wide application of new drugs such as proteasome inhibitors and immunomodulators, the survival time of MM patients has been prolonged obviously. Cellular immunotherapies like genetically modified T cell, activated marrow-infiltrating lymphocytes, dendritic cell vaccines, natural killer cells and donor lymphocyte infusion have made great progresses in the field of MM management recently, following the stable advance in clinical trials. This review discusses the recent progress of cellular immunotherapy for MM.
